This is a preview. Log in through your library . Abstract Amyloid-β (Aβ) fibrils exhibit self-propagating, molecular-level polymorphisms that may contribute to variations in clinical and pathological ...
The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal antibody that ...
The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer’s disease. On its ...
Cerebral amyloid angiopathy is a major cause of hemorrhagic stroke, a frequent contributor to age-related cognitive impairment, and a key component in adverse responses to beta-amyloid (Aβ) ...
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first blood test aiding Alzheimer's diagnosis by detecting amyloid plaques, offering a less invasive alternative to PET scans. The test ...
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) ...
Scientists in Japan found that arginine, a common amino acid already used in supplements and medicine, reduced harmful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results